[go: up one dir, main page]

WO2025211983A1 - Peptides avec activité antitumorale - Google Patents

Peptides avec activité antitumorale

Info

Publication number
WO2025211983A1
WO2025211983A1 PCT/RU2024/000181 RU2024000181W WO2025211983A1 WO 2025211983 A1 WO2025211983 A1 WO 2025211983A1 RU 2024000181 W RU2024000181 W RU 2024000181W WO 2025211983 A1 WO2025211983 A1 WO 2025211983A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
peptide
cancer
subject
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/RU2024/000181
Other languages
English (en)
Russian (ru)
Inventor
Альберт Добаевич БОЛАТЧИЕВ
Николай Николаевич ДИДЕНКО
Елизавета Юрьевна БОЛАТЧИЕВА
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Obshchestvo S Ogranichennoj Otvetstvennostyu "albogene"
Original Assignee
Obshchestvo S Ogranichennoj Otvetstvennostyu "albogene"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2024109240A external-priority patent/RU2840111C1/ru
Application filed by Obshchestvo S Ogranichennoj Otvetstvennostyu "albogene" filed Critical Obshchestvo S Ogranichennoj Otvetstvennostyu "albogene"
Publication of WO2025211983A1 publication Critical patent/WO2025211983A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Definitions

  • the invention relates to the chemistry of organic compounds, pharmacology and medicine and concerns new peptides characterized by antitumor activity, which, in particular, can be used for the prevention and treatment of tumor diseases in a subject.
  • Cancer is one of the most common diseases worldwide, and currently widely used treatment methods include chemotherapy, surgery, radiation therapy, hematopoietic stem cell transplantation, and immunotherapy. Tumors pose a significant threat to human health and remain one of the most dangerous diseases with a high mortality rate. Therefore, the discovery of new, highly effective, and high-quality anticancer drugs is an important topic of research worldwide. Research into the molecular mechanisms of cancer is actively underway. Despite the progress made, many of the currently developed treatments rely on surgical intervention.
  • Peptides are increasingly being developed for use as therapeutic agents for the treatment of many diseases, including cancer.
  • Therapeutic peptides offer the advantages of target specificity and low toxicity. Peptides can induce cell death through numerous mechanisms, including membrane disruption and subsequent necrosis, apoptosis, inhibition of tumor angiogenesis, immune regulation, disruption of cellular signaling pathways, cell cycle regulation, DNA repair pathways, or cell death pathways [Caroline M. Li et al/ Novel Peptide Therapeutic Approaches for Cancer Treatment/ Cells. 2021 Nov; 10(11): 2908].
  • the objective of the present invention is to develop and create new effective antitumor agents that are promising for use in clinical practice for the treatment and/or prevention of antitumor diseases.
  • the specified technical result is achieved by developing and creating a peptide with antitumor activity, having the sequence SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 13, 14 or 15, or its pharmaceutically acceptable salt.
  • the disease is melanoma, metastatic pancreatic adenocarcinoma, lung carcinoma, breast cancer, colorectal cancer, prostate cancer, liver cancer, esophageal cancer.
  • the subject is a human being.
  • the subject of the present invention is also a pharmaceutical composition with antitumor activity for the treatment and/or prevention of a tumor disease in a subject, containing an effective amount of a peptide according to the invention and at least one pharmaceutically acceptable excipient.
  • the disease is melanoma, metastatic pancreatic adenocarcinoma, lung carcinoma, breast cancer, colorectal cancer, prostate cancer, liver cancer, esophageal cancer.
  • amino acid also refers to naturally occurring amino acids (including both L-amino acids and D-amino acids).
  • Amino acids are designated by standard abbreviations, for example: arginine (Arg; R), leucine (Leu; L), lysine (Lys; K), phenylalanine (Phe; F), tryptophan (Trp; W), isoleucine (He; I), valine (Vai; V), proline (Pro; P), tyrosine (Tyr; Y), methionine (Met; M), serine (Ser; S), alanine (Ala; A), aspartic acid (Asp; D), glycine (Gly; G).
  • isolated and purified when applied to a substance (e.g., a peptide, etc.) indicate that the substance is substantially free of at least one substance that may also be present in the natural source.
  • an isolated or purified peptide refers to a peptide that is substantially free of other cellular material, such as carbohydrate, lipid, and other contaminating proteins, from the cell or tissue source from which the peptide is obtained. If the peptide is chemically synthesized, an isolated or purified peptide refers to a peptide that is substantially free of a precursor substance or other chemical.
  • an isolated or purified peptide that is substantially free of culture medium includes peptide preparations that contain culture medium less than about 20%, 10%, or 5%, 3%, 2%, or 1% (based on dry weight) of the volume of the peptide preparation.
  • radiolabeled compounds of the present invention can be prepared using methods well known to those skilled in the art. Labeled compounds can be prepared using the procedures described herein by simply replacing unlabeled reagents with the appropriate labeled reagents.
  • the compounds of the present invention may exist in free form or, if desired, in the form of a pharmaceutically acceptable salt or other derivative.
  • pharmaceutically acceptable salt refers to those salts which, within the limits of medical judgment, are suitable for use in contact with human and animal tissues without undue toxicity, irritation, allergic reaction, etc., and which meet a reasonable balance of benefit and risk.
  • Pharmaceutically acceptable salts of amines, carboxylic acids, phosphonates, and other types of compounds are well known in medicine. Salts can be prepared in situ during the isolation or purification of the compounds of the invention, and can also be prepared separately by reacting the free acid or free base of the compound of the invention with a suitable base or acid, respectively.
  • Examples of pharmaceutically acceptable, non-toxic acid salts include salts of the amino group formed with inorganic acids such as hydrochloric, hydrobromic, phosphoric, sulfuric, and perchloric acids, or organic acids such as acetic, oxalic, maleic, tartaric, succinic, or malonic acids, or obtained by other methods used in this field, for example, by ion exchange.
  • inorganic acids such as hydrochloric, hydrobromic, phosphoric, sulfuric, and perchloric acids
  • organic acids such as acetic, oxalic, maleic, tartaric, succinic, or malonic acids, or obtained by other methods used in this field, for example, by ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanate, hydroiodide, 2-hydroxyethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, per
  • Typical alkali and alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and others.
  • pharmaceutically acceptable salts may contain, if desired, non-toxic ammonium, quaternary ammonium, and amine cations obtained using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates, and aryl sulfonates.
  • the claimed peptides can be incorporated into other large molecules (proteins, peptides, nucleic acids, carbohydrates, lipids) without altering their pharmacological activity or to impart new properties. Furthermore, derivatives of the claimed peptide can be obtained by chemical modification of the terminal amino acid regions.
  • the peptides of the invention can be synthesized with additional chemical groups located at their amine and/or carboxyl ends, for increasing the stability, bioavailability, and/or affinity of peptides.
  • additional chemical groups such as carbobenzoxyl, dansyl, or tert-butyloxycarbonyl groups can be added to the amino termini of peptides.
  • an acetyl group or a 9-fluorenylmethoxycarbonyl group can be placed at the amino termini of peptides.
  • a hydrophobic group, tert-butyloxycarbonyl, or amide group can be added to the carboxyl termini of peptides.
  • a “therapeutically effective amount” is defined as the amount of a compound administered or delivered to a patient that is most likely to produce the desired response to treatment. The exact amount required may vary from subject to subject depending on the patient's age, body weight, and general condition, the severity of the disease, the method of administration, combination therapy with other drugs, etc.
  • a “prophylactically effective amount” is defined as the amount of a compound administered or delivered to a patient that is most likely to produce the desired tumor prophylaxis response. The exact amount required may vary from subject to subject depending on the patient's age, body weight, and general condition, the method of administration, the combination with other drugs, etc.
  • a therapeutically or prophylactically effective amount is the amount that will effectively prevent tumor disease.
  • treatment and “therapy” cover the treatment of pathological conditions in mammals, preferably in humans, and include: a) blocking (stopping) the course of the disease, b) alleviating the severity of the disease, i.e. inducing regression of the disease.
  • prophylaxis encompass the elimination of risk factors, as well as prophylactic treatment of subclinical stages of disease in humans, aimed at reducing the likelihood of developing clinical stages of the disease.
  • Patients for prophylactic therapy are selected based on factors that, based on known data, increase the risk of developing clinical stages of the disease compared to the general population.
  • Preventive therapy includes a) primary prevention and b) secondary prevention.
  • Primary prevention Secondary prevention is defined as prophylactic treatment in patients who have not yet reached the clinical stage of the disease. Secondary prevention is the prevention of recurrence of the same or a similar clinical state of the disease.
  • risk reduction encompasses therapies that reduce the incidence of clinical disease. Examples of risk reduction include primary and secondary disease prevention.
  • the methods and compositions of the present invention are suitable for treating a malignant tumor
  • the treatment is considered effective if it achieves clinical benefits, such as reducing the size, spread, or metastatic properties of a malignant tumor, slowing the progression of a malignant tumor, alleviating the clinical symptoms of a malignant tumor, prolonging the survival period, or suppressing postoperative recurrences in a subject.
  • clinical benefits such as reducing the size, spread, or metastatic properties of a malignant tumor, slowing the progression of a malignant tumor, alleviating the clinical symptoms of a malignant tumor, prolonging the survival period, or suppressing postoperative recurrences in a subject.
  • effectiveness means that the treatment slows or prevents the formation of a malignant tumor, or prevents or alleviates the clinical symptoms of a malignant tumor.
  • Efficacy is determined relative to any generally known methods for diagnosing or treating a specific tumor type.
  • prevention includes any activity that alleviates the burden of mortality or morbidity associated with malignant tumors. Prevention can be carried out at the primary, secondary, and tertiary preventive levels. While primary prevention helps to avoid the development of a disease, secondary and tertiary prevention includes the prevention of disease progression and the onset of symptoms, as well as activities designed to reduce the adverse effects of an existing disease by restoring function and reducing disease-associated complications. Conversely, prevention can include alleviating the severity of a specific disorder, such as extensive prophylactic therapy designed to reduce tumor growth and metastasis.
  • treatment and/or prevention (prophylaxis) of a malignant tumor and/or prevention (prophylaxis) of its postoperative recurrence include any of the events such as inhibition of malignant cell proliferation, tumor regression, initiation of remission and suppression of the development of a malignant tumor, tumor regression, as well as reduction or inhibition of metastasis, suppression of postoperative Recurrence of malignant tumors and prolongation of survival.
  • Effective treatment and/or prevention (prophylaxis) of malignant tumors reduces mortality, improves the prognosis of individuals with malignant tumors, lowers the level of tumor markers in the blood, and alleviates detectable symptoms associated with malignant tumors.
  • alleviation or improvement of symptoms constitutes effective treatment and/or prevention (prophylaxis) and includes a state in which symptoms are stable or improved, in particular by 10%, 20%, 30%, or more.
  • peptide described herein can exist and is often used in the form of its pharmaceutically acceptable derivatives, such as salts, prodrugs, metabolites, esters, ethers, hydrates, polymorphs, solvates, complexes, enantiomers, or other pharmaceutically acceptable derivatives. Therefore, reference to a peptide described herein is intended to include such pharmaceutically acceptable salts, prodrugs, metabolites, esters, ethers, hydrates, polymorphs, solvates, complexes, enantiomers, or any other pharmaceutically acceptable derivatives thereof.
  • the invention also relates to pharmaceutical compositions that comprise a peptide of the invention (or a prodrug, a pharmaceutically acceptable salt or other pharmaceutically acceptable derivative) and one or more pharmaceutically acceptable carriers, adjuvants, solvents and/or excipients, such that can be administered to a patient together with the compound that is the essence of this invention and that do not destroy the pharmacological activity of this compound and are non-toxic when administered in doses sufficient to deliver a therapeutic amount of the compound.
  • compositions specified in this invention comprise the peptides of the present invention together with pharmaceutically acceptable carriers, which may include any solvents (in particular water), diluents, dispersions or suspensions, surfactants, isotonic agents, thickeners and emulsifiers, preservatives, binders, lubricants, etc., suitable for a particular dosage form.
  • pharmaceutically acceptable carriers may include any solvents (in particular water), diluents, dispersions or suspensions, surfactants, isotonic agents, thickeners and emulsifiers, preservatives, binders, lubricants, etc., suitable for a particular dosage form.
  • Materials that can serve as pharmaceutically acceptable carriers include, but are not limited to, mono- and oligosaccharides, as well as derivatives thereof; gelatin; talc; excipients such as cocoa butter and suppository wax; oils such as peanut, cottonseed, sesame, olive, corn and soybean oil and others; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and Aluminum hydroxide; alginic acid; depyrogenated water; isotonic solution, Ringer's solution; alcohol and phosphate buffer solutions.
  • excipients such as cocoa butter and suppository wax
  • oils such as peanut, cottonseed, sesame, olive, corn and soybean oil and others
  • glycols such as propylene glycol
  • esters such as ethyl oleate and ethyl laurate
  • agar buffering agents such as magnesium hydrox
  • composition may also contain other non-toxic compatible lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as dyes, release agents, film-forming agents, sweeteners, flavorings and fragrances, preservatives and antioxidants.
  • non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as dyes, release agents, film-forming agents, sweeteners, flavorings and fragrances, preservatives and antioxidants.
  • aqueous suspensions, isotonic saline solutions or sterile injection solutions are used, the compatible agents of which contain pharmacological agents, for example, propylene glycol or butylene glycol.
  • compositions of the invention may include a peptide of the present invention conjugated to polyethylene glycol, namely, conjugation of the N-terminus of the peptide to polyethylene glycol (hereinafter referred to as PEG) [ACS Appl. Mater. Interfaces 2020, 12, 41, 46991-47001; https://doi.org/10.1021/acsami.0c13492].
  • PEG polyethylene glycol
  • PEG is highly soluble in water and many organic solvents, non-toxic and non-immunogenic. PEGylation of biologically active compounds allows to increase metabolic stability by creating steric hindrances that protect the molecule from proteases, and, thus, to increase circulation time in vivo.
  • the compounds of the present invention are antitumor agents and are therefore useful for the treatment and/or prevention of tumor disease.
  • the present invention relates to methods for the treatment and/or prevention of a malignant tumor and/or prevention, in particular its postoperative recurrence, which comprise administering to a subject a therapeutically or prophylactically effective amount of a peptide of the present invention or a pharmaceutical composition of the present invention.
  • the invention also relates to methods for treating or preventing a tumor in a subject, comprising administering to the subject an effective amount of a peptide of the invention.
  • the subject is a human, and the peptide of the invention can be delivered intravenously, intramuscularly, orally, epidermally, subcutaneously, intraosseously, intraperitoneally, intraocularly, by inhalation, intranasally and/or sublingually, as well as by systemic administration or local administration in close proximity to target sites, but is not limited to the above.
  • the route of administration includes subcutaneous or intravenous injection. Administration can be carried out by a single administration or divided into multiple administrations.
  • Malignant tumors for the treatment of which the peptides of the invention can be used include bladder cancer, breast cancer, cervical cancer, ovarian cancer, acute myeloid leukemia, chronic myeloid leukemia (CML), lymphoma, colon cancer, gastric cancer, esophageal cancer, liver cancer, melanoma, lung cancer, lymphoma, osteosarcoma, prostate cancer, pancreatic cancer, renal cell carcinoma, kidney cancer, hepatocellular carcinoma, non-small cell lung cancer and gastrointestinal stromal tumors, soft tissue tumors, etc., but are not limited to the above.
  • bladder cancer breast cancer, cervical cancer, ovarian cancer, acute myeloid leukemia, chronic myeloid leukemia (CML), lymphoma, colon cancer, gastric cancer, esophageal cancer, liver cancer, melanoma, lung cancer, lymphoma, osteosarcoma, prostate cancer, pancreatic cancer, renal cell carcinoma, kidney cancer, hepatocellular carcinoma, non-small cell lung
  • the compound or compositions described herein can also be used for prophylactic purposes. Accordingly, the compound or composition can be administered to a subject potentially at risk of developing a tumor.
  • the compounds of the invention may be administered via a pharmaceutical composition in any pharmaceutical dosage form by any route of administration.
  • Dosage forms typically include a pharmaceutically acceptable carrier suitable for the particular dosage form selected.
  • a compound of the invention may be administered daily for the period of time necessary for treatment and/or prophylaxis. diseases relevant to the patient, including courses of therapy lasting days, months, years, or the patient's entire life.
  • Routes of administration include, but are not limited to, intravenous, intramuscular, oral, epidermal, subcutaneous, intraosseous, intraperitoneal, intraocular, inhalation, intranasal, and/or sublingual.
  • the preferred route of administration is intravenous.
  • the invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a daily dose of said compound in the form of a fixed dosage unit, and to a combination comprising said pharmaceutical composition or said compound.
  • said composition for use in accordance with the invention is administered once daily at a dosage of 1 mg or more of the selected compound according to the invention.
  • the preferred dosage is 1-500 mg.
  • the most preferred dosage is 10-200 mg.
  • One or more additional pharmacologically active agents may be administered in combination with the peptide of the invention.
  • any additional single or multiple active agents other than the compounds of the invention including, but not limited to, other antitumor drugs, antibodies, hormonal therapy agents, and others, may be used in any combination with the compound of the invention in a single or separate dosage form, allowing for the simultaneous or sequential therapeutic action of the active agents.
  • nucleotide sequences encoding the amino acid sequences of the claimed peptides can be synthesized. These nucleotide sequences can be introduced into cells (using vectors or native nucleic acids), and the cells thus transformed can be used to express the claimed peptides. These vectors and nucleotide sequences can be introduced into the human body (and other living organisms) for direct in vivo expression of the claimed peptides. These methods are also well known to those skilled in the art.
  • the peptides of the present invention can be isolated from host cells or the products of a synthetic reaction, after they have been produced in host cells using recombinant DNA technology or after they have been chemically synthesized. That is, the peptides of the present invention can be purified or isolated in such a way that they are substantially free of other proteins and fragments thereof from the host cell, or any other chemicals.
  • the peptides of the invention were synthesized by solid-phase Fmoc synthesis using a JBMS-96-A automated synthesizer (Jianbang Pharmacy Technology Co., Ltd.). The peptides were purified (purity >95%) using reversed-phase high-performance liquid chromatography (Table 2).
  • HPLC of the peptides according to the invention was performed on a YMC-Triart C18 column (4.6*250mm*5um), eluting with 0.1% trifluoroacetic acid in 100% water (solvent A) and 0.1% trifluoroacetic acid in 100% acetonitrile (solvent B), at a flow rate of 1 ml/min.
  • 50 ⁇ l of nutrient medium supplemented with 10% FBS was added to the wells instead of the active substance.
  • the plates with samples were placed in an incubator overnight (16 hours) at 37°C and 5% CO2 .
  • the optical density of the solution in the wells of the plate was measured at a wavelength of 450 nm, subtracting the optical density at 620 nm as background, using a Cytation 1 multifunctional photometer-imager and expressed as a percentage relative to the positive control.
  • the results are presented in Tables 3-5.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à la chimie des composés organiques, à la pharmacologie et à la médecine, et concerne de nouveaux peptides caractérisés par une activité antitumorale qui sont notamment utilisés dans la prévention et le traitement de maladies tumorales chez un sujet. La présente invention concerne en outre l'utilisation de peptides selon l'invention afin de traiter des maladies tumorales, ainsi que des compositions pharmaceutiques pour traiter des maladies tumorales comprenant les peptides selon la présente invention.
PCT/RU2024/000181 2024-04-05 2024-06-06 Peptides avec activité antitumorale Pending WO2025211983A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2024109240A RU2840111C1 (ru) 2024-04-05 Пептиды с противоопухолевой активностью
RU2024109240 2024-04-05

Publications (1)

Publication Number Publication Date
WO2025211983A1 true WO2025211983A1 (fr) 2025-10-09

Family

ID=97267611

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2024/000181 Pending WO2025211983A1 (fr) 2024-04-05 2024-06-06 Peptides avec activité antitumorale

Country Status (1)

Country Link
WO (1) WO2025211983A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006108270A1 (fr) * 2005-04-11 2006-10-19 Pharmagap Inc. Inhibiteurs de proteines kinases et leurs utilisations
EA202091833A1 (ru) * 2018-02-21 2020-11-25 Имматикс Биотехнолоджис Гмбх Пептиды и комбинации пептидов неканонического происхождения для применения в иммунотерапии различных видов рака
WO2023277514A1 (fr) * 2021-06-28 2023-01-05 고려대학교 산학협력단 Peptide ayant une activité anticancéreuse et son utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006108270A1 (fr) * 2005-04-11 2006-10-19 Pharmagap Inc. Inhibiteurs de proteines kinases et leurs utilisations
EA202091833A1 (ru) * 2018-02-21 2020-11-25 Имматикс Биотехнолоджис Гмбх Пептиды и комбинации пептидов неканонического происхождения для применения в иммунотерапии различных видов рака
WO2023277514A1 (fr) * 2021-06-28 2023-01-05 고려대학교 산학협력단 Peptide ayant une activité anticancéreuse et son utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PRITI MUDGIL ET AL.: "Molecular binding mechanism and identification of novel anti- hypertensive and anti-inflammatory bioactive peptides from camel milk protein hydrolysates", LWT - FOOD SCIENCE AND TECHNOLOGY, vol. 112, September 2019 (2019-09-01), pages 108193, XP085733570, DOI: doi.org/10.1016/j.lwt. 2019.05.09 1 *

Similar Documents

Publication Publication Date Title
KR20160075506A (ko) 면역조절제로서 사이클릭 펩티도미메틱 화합물
CN108383893A (zh) 用于治疗实体瘤的fap-活化的蛋白酶体抑制剂
MX2011004019A (es) Conjugados de etoposido y doxorubicina para entrega de farmacos.
CN105308063A (zh) Wt1抗原肽缀合物疫苗
CN113549129B (zh) 一种d-构型抗肿瘤肽及其制备方法和应用
TW201730164A (zh) 新穎念珠藻素及共軛物、其製備與其治療用途
CA2743986A1 (fr) Nonapeptide presentant une activite antitumorale
US20250250299A1 (en) Macrocyclic immunomodulators
JP6701083B2 (ja) 抗リンパ腫ペプチド
KR102607901B1 (ko) 신규한 올리고펩티드 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
EP2010203A2 (fr) Peptides macrocycliques et leurs procédés de fabrication et d'utilisation
US11174291B2 (en) Silstatin compounds
RU2840111C1 (ru) Пептиды с противоопухолевой активностью
WO2025211983A1 (fr) Peptides avec activité antitumorale
AU770920C (en) Phenylalanine derivatives
US20250213645A1 (en) Pharmaceutical composition for modulating immune response
CN113908253A (zh) 环状鞘脂激活蛋白原肽及其用途
JP3939354B2 (ja) 抗腫瘍性ペプチド
US11208443B2 (en) NAF-1 derived peptides and uses thereof
JP2001131066A (ja) アポトーシス増強剤
KR20230042650A (ko) 면역반응을 조절하기 위한 약학적 조성물
WO2023088236A1 (fr) Ligand peptidique bicyclique de mt1-mmp et son conjugué
ES2952984T3 (es) Péptidos anticancerígenos y usos de los mismos
KR20250117319A (ko) 미토콘드리아 기능 개선 펩타이드의 항암 용도
WO2022170108A1 (fr) Macrocycles peptidomimétiques et leurs utilisations dans la prévention de lésion par irradiation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24934341

Country of ref document: EP

Kind code of ref document: A1